Advertisement
Organisation › Details
MedinCell S.A. (Euronext: MEDCL)
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities. *
Start | 2014-01-26 existent | |
Group | MedinCell (Group) | |
Industry | BEPO® technology | |
Industry 2 | drug delivery technology (drug formulation technology) | |
Person | Douat, Christophe (MedinCell 201810 Board Chairman) | |
Person 2 | Arango, Jaime (MedinCell 202005 CFO) | |
Region | Montpellier | |
Country | France | |
Street | 3 rue des Frères Lumière | |
City | 34830 Jacou | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2019-11-28) |
* Document for »About Section«: MedinCell S.A.. (11/28/19). "Press Release: MedinCell Receives $19 Million Grant for Its mdc-WWM Program". Montpellier. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for MedinCell (Group)
- [1] MedinCell S.A.. (11/30/22). "Press Release: Additional US$ 4 Million Received for Next Development Steps of MedinCell’s 6-month Active Injectable Bioresorbable Subcutaneous Contraceptive". Montpellier....
- [2] MedXCell S.A.. (3/11/22). "Press Release: MedXCell SA Is Proud to Annonce the Arrival of Andrew Galzaka and John D. McMannis as New Members of the Board and Pierre J.Magistretti as New Scientific Advisor". Montreux....
- [3] MedXCell S.A.. (6/4/21). "Press Release: MedXCell SA Has Successfully Closed a CHF 5.3 Million Series A". Montreux....
- [4] MedinCell S.A.. (2/11/21). "Press Release: Tremendous Success for MedinCell’s €30 Million Capital Increase for Qualified Investors". Montpellier....
- [5] MedinCell S.A.. (6/16/20). "Press Release: MedinCell Announces the Great Success of Its Capital Increase and Raises 15.6 M€ [Not for publication nor to distribution in the United States, Canada, Japan or Australia]". Montpellier....
- [6] MedinCell S.A.. (5/27/20). "Press Release: MedinCell Secures €10.9 Million Non-Dilutive Financing". Montpellier....
- [7] MedinCell S.A.. (3/25/20). "Press Release: MedinCell Receives $ 6.4 Million Grant from Unitaid to Fight Malaria". Montpellier....
- [8] MedinCell S.A.. (11/28/19). "Press Release: MedinCell Receives $19 Million Grant for Its mdc-WWM Program". Montpellier....
- [9] Euronext N.V.. (10/8/18). "Press Release: Medincell Lists on Euronext Paris. €30 Million Raised, Market Capitalisation €144 Million". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top